Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLogie, Emilieen_US
dc.contributor.authorChirumamilla, Chandra S.en_US
dc.contributor.authorPerez-Novo, Claudinaen_US
dc.contributor.authorShaw, Priyankaen_US
dc.contributor.authorDeclerck, Kenen_US
dc.contributor.authorPalagani, Ajayen_US
dc.contributor.authorRangarajan, Savithrien_US
dc.contributor.authorCuypers, Barten_US
dc.contributor.authorDe Neuter, Nicolasen_US
dc.contributor.authorFazil, Mobashar Hussain Urf Turabeen_US
dc.contributor.authorVerma, Navin Kumaren_US
dc.contributor.authorBogaerts, Annemieen_US
dc.contributor.authorLaukens, Krisen_US
dc.contributor.authorOffner, Fritzen_US
dc.contributor.authorVan Vlierberghe, Pieteren_US
dc.contributor.authorVan Ostade, Xaveeren_US
dc.contributor.authorBerghe, Wim Vandenen_US
dc.identifier.citationLogie, E., Chirumamilla, C. S., Perez-Novo, C., Shaw, P., Declerck, K., Palagani, A., Rangarajan, S., Cuypers, B., De Neuter, N., Fazil, M. H. U. T., Verma, N. K., Bogaerts, A., Laukens, K., Offner, F., Van Vlierberghe, P., Van Ostade, X. & Berghe, W. V. (2021). Covalent cysteine targeting of Bruton’s tyrosine kinase (BTK) family by withaferin-A reduces survival of glucocorticoid-resistant multiple myeloma MM1 cells. Cancers, 13(7), 1618-.
dc.description.abstractMultiple myeloma (MM) is a hematological malignancy characterized by plasma cells’ uncontrolled growth. The major barrier in treating MM is the occurrence of primary and acquired therapy resistance to anticancer drugs. Often, this therapy resistance is associated with constitutive hyperactivation of tyrosine kinase signaling. Novel covalent kinase inhibitors, such as the clinically approved BTK inhibitor ibrutinib (IBR) and the preclinical phytochemical withaferin A (WA), have, therefore, gained pharmaceutical interest. Remarkably, WA is more effective than IBR in killing BTK-overexpressing glucocorticoid (GC)-resistant MM1R cells. To further characterize the kinase inhibitor profiles of WA and IBR in GC-resistant MM cells, we applied phosphopeptidome- and transcriptome-specific tyrosine kinome profiling. In contrast to IBR, WA was found to reverse BTK overexpression in GC-resistant MM1R cells. Furthermore, WA-induced cell death involves covalent cysteine targeting of Hinge-6 domain type tyrosine kinases of the kinase cysteinome classification, including inhibition of the hyperactivated BTK. Covalent interaction between WA and BTK could further be confirmed by biotin-based affinity purification and confocal microscopy. Similarly, molecular modeling suggests WA preferably targets conserved cysteines in the Hinge-6 region of the kinase cysteinome classification, favoring inhibition of multiple B-cell receptors (BCR) family kinases. Altogether, we show that WA’s promiscuous inhibition of multiple BTK family tyrosine kinases represents a highly effective strategy to overcome GC-therapy resistance in MM.en_US
dc.description.sponsorshipMinistry of Education (MOE)en_US
dc.description.sponsorshipMinistry of Health (MOH)en_US
dc.description.sponsorshipNational Medical Research Council (NMRC)en_US
dc.description.sponsorshipNational Research Foundation (NRF)en_US
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
dc.titleCovalent cysteine targeting of Bruton’s tyrosine kinase (BTK) family by withaferin-A reduces survival of glucocorticoid-resistant multiple myeloma MM1 cellsen_US
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.description.versionPublished versionen_US
dc.subject.keywordsWithaferin Aen_US
dc.subject.keywordsBruton’s Tyrosine Kinaseen_US
dc.description.acknowledgementThis research was funded by Foundation Against Cancer (Belgium), grant number 7872, Hercules Foundation, grant number AUHA/13/012 and Research Foundation Flanders, grant number FWO G1179120N, G059713N. N.K.V. acknowledges funding support from the Singapore Ministry of Education (MOE) under its MOE Academic Research Fund (AcRF) Tier 2 Grant (grant number MOE2017-T2-2-004) and the National Research Foundation Singapore under its Open Fund Large Collaborative Grant (grant number OFLCG18May-0028) and administered by the Singapore Ministry of Health’s National Medical Research Council (NMRC).en_US
item.fulltextWith Fulltext-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
cancers-13-01618-v2.pdf4.81 MBAdobe PDFView/Open

Page view(s)

Updated on Jul 6, 2022

Download(s) 50

Updated on Jul 6, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.